CHICAGO TRUST Co NA Raises Holdings in Eli Lilly and Company (NYSE:LLY)

CHICAGO TRUST Co NA lifted its holdings in shares of Eli Lilly and Company (NYSE:LLYFree Report) by 6.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,781 shares of the company’s stock after buying an additional 392 shares during the period. Eli Lilly and Company comprises 1.0% of CHICAGO TRUST Co NA’s investment portfolio, making the stock its 18th biggest holding. CHICAGO TRUST Co NA’s holdings in Eli Lilly and Company were worth $6,008,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of LLY. Lynx Investment Advisory acquired a new stake in shares of Eli Lilly and Company in the 2nd quarter worth approximately $32,000. LGT Financial Advisors LLC acquired a new position in Eli Lilly and Company during the second quarter worth $36,000. Morton Brown Family Wealth LLC raised its holdings in Eli Lilly and Company by 45.5% during the second quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock worth $41,000 after purchasing an additional 15 shares during the last quarter. Unique Wealth Strategies LLC acquired a new position in Eli Lilly and Company during the second quarter worth $45,000. Finally, Redmont Wealth Advisors LLC acquired a new position in Eli Lilly and Company during the first quarter worth $40,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Bank of America lifted their price objective on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $885.00 price objective on shares of Eli Lilly and Company in a report on Monday, September 16th. Citigroup initiated coverage on Eli Lilly and Company in a report on Friday, September 13th. They set a “buy” rating and a $1,060.00 price objective for the company. Berenberg Bank raised their price target on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. Finally, BMO Capital Markets raised their price target on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $979.29.

Get Our Latest Research Report on Eli Lilly and Company

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $932.06 on Friday. Eli Lilly and Company has a twelve month low of $547.61 and a twelve month high of $972.53. The stock has a market capitalization of $885.83 billion, a P/E ratio of 137.27, a PEG ratio of 2.79 and a beta of 0.42. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. The business’s fifty day moving average price is $910.84 and its 200 day moving average price is $852.86.

Eli Lilly and Company (NYSE:LLYGet Free Report) last issued its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The firm had revenue of $11.30 billion for the quarter, compared to analysts’ expectations of $9.83 billion. As a group, research analysts anticipate that Eli Lilly and Company will post 16.49 earnings per share for the current year.

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

See Also

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYFree Report).

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.